 |
|
 |
|
|
|
 What is RSS?
Foundation status offered to 38 more trusts
A further 38 hospital have been invited to apply for foundation trust status after winning three stars in the recent NHS performance ratings...(more)
Pfizer ends obesity drug partnership
Pfizer has pulled out of its partnership with UK biotech company Phytopharm to develop an obesity treatment based on a cactus plant...(more)
Savings boost GSK outlook
GlaxoSmithKline has increased its predicted earnings for 2003 despite a virtually unchanged turnover in the second quarter...(more)
Paediatric trials to be mandatory in US
Plans to make clinical trials mandatory for all drugs intended for children are progressing in the US...(more)
Doubts over pipeline cloud Aventis results
Aventis may struggle to replace revenue from its ageing blockbusters despite a strong performance in the second quarter, according to analysts...(more)
Heart failure guidelines recommend ACE inhibitors
ACE inhibitors have been recommended as first line treatment for chronic heart failure as part of a comprehensive set of NICE guidelines for diagnosing and treating the disease...(more)
Weak dollar contains Sanofi growth
The weakness of the US dollar more than halved Sanofi-Synthelabo's earnings in the first half of this year, but disguised strong underlying growth across its portfolio of products...(more)
Smooth transition from old to new for AstraZeneca
Growth in new products are helping to plug the sizeable gap left by three of AstraZeneca's ageing blockbusters Prilosec (Losec), Zestril and Nolvadex...(more)
BMS and Lilly exceed expectations
Strong sales of established and new products in the second quarter saw both Bristol-Myers Squibb and Eli Lilly beat analysts' earning forecasts...(more)
Media training company launched
A new training agency specialising in preparing pharmaceutical spokespeople to deal with modern media techniques has been launched...(more)
Celebrex to gain orphan drug indication
Pfizer's blockbuster arthritis drug Celebrex is set to gain a European orphan drug licence for the treatment of a rare pre-cancerous condition, after receiving the backing of the Committee for Proprietary Medicinal Products...(more)
Industry could gain access to yellow card data
The pharmaceutical industry could be granted access to data from the UK's Yellow Card adverse effect warning system to assist the development of safer and more targeted drugs...(more)
Challenging second quarter for big pharma
Generic competition and wholesaler de-stocking are among the problems besetting two of the industry's biggest hitters, GlaxoSmithKline and AstraZeneca...(more)
NICE suspends breast cancer appraisal to await data
A NICE appraisal of breast cancer drugs is set to be delayed by two years to allow pharmaceutical companies more time to produce clinical trial data...(more)
Breakthrough in consultant contract talks
Doctors' leaders have declared a breakthrough in the long-running and bitter dispute over the new consultants' contract...(more)
NHS leaders pour scorn on star ratings
New star ratings for all NHS trusts have been attacked by leaders in primary and secondary care, who say they fail to reflect the overall standard of patient care...(more)
Liver test takes shine off Exanta
AstraZeneca has admitted that patients on its new anti-clotting drug Exanta will need liver tests, denting the drug's profile as a medical advance...(more)
New R&D chief as Merck files Erbitux
German pharmaceutical Merck KgaA has appointed a new head of clinical research and development following a major R&D re-organisation. ..(more)
Seroxat safety review widens
The European regulatory authority EMEA has launched a safety review of GlaxoSmithKline's Seroxat that could lead to the withdrawal of the blockbuster antidepressant...(more)
PR heavyweights launch new agency
Former managing directors of Shire Health London and Cohn & Wolfe Healthcare have joined forces to launch a new independent, full-service PR agency...(more)
PCTs to hold balance of power in community pharmacy
Pharmacy leaders have welcomed plans to protect local pharmacies from greater competition, but say crucial detail must now be agreed to ensure patient services do not suffer...(more)
US approval for breakthrough diabetes device
The first integrated glucose meter and insulin pump has been approved by the FDA, bringing the goal of an 'artificial pancreas' one step closer...(more)
Schering's Angeliq approved in Europe
Schering's new low dose HRT product Angeliq has gained mutual recognition in the European Union, with launches expected across the continent this autumn...(more)
Foundation hospitals survive Labour revolt
Plans for foundation hospitals have been narrowly passed by the House of Commons despite a revolt by Labour MPs that gave the government its smallest majority to date...(more)
GSK and Novartis settle over Augmentin
GlaxoSmithKline has reached an agreement with Novartis in its court action over stolen trade secrets for its antibiotic Augmentin...(more)
AstraZeneca buoyed by Crestor clearance
AstraZeneca's new statin drug has received unanimous approval by a key FDA panel, and now looks set to be launched in the US market this year...(more)
Call for free price-setting across Europe
Pharmaceutical companies should be allowed to set their own prices in all European Union countries in order to bring a single market one step closer, the European Commission has said...(more)
Pharma urged to reduce animal testing
The pharmaceutical industry should test more drugs in humans at a pre-clinical stage to reduce numbers of primates used, a UK government advisory body has said...(more)
Profits continue to plummet at Schering-Plough
Schering-Plough has issued its third earnings warning this year as it continues to suffer under an onslaught from generic competition...(more)
AZ settles $355m fraud case
AstraZeneca has settled the case relating to fraudulent sales of its prostate cancer drug Zoladex, and will pay a total of $354.9 million...(more)
BMA elects new leader
A consultant surgeon at Halton Hospital in Cheshire has been elected as new Chairman of the BMA to replace Dr Ian Bogle...(more)
British Biotech snaps up Vernalis, loses name
British Biotech and Vernalis are to merge, marking a continuation of much-needed consolidation with the UK biotech sector...(more)
AstraZeneca rises on Crestor hopes
AstraZeneca made significant stock market gains following indications its new superstatin Crestor will receive a positive review from US regulatory authorities...(more)
GSK gives way on Paxil patents
New measures by the FDA to speed up patient access to generic medicines have claimed their first scalp after GlaxoSmithKline withdrew three patents related to its blockbuster Paxil...(more)
Pharma executive proves controversial choice for AIDS leader
President George Bush has appointed Randy Tobias, former chief executive of Eli Lilly, to lead US efforts to combat AIDS in the developing world...(more)
MHRA must engage more with public, say MPs
The MHRA has come under criticism from MPs over its efforts to communicate with the public and lead improvements in medicines safety...(more)
Schering-Plough plays down Zetia label change
Schering-Plough has changed the labelling of its new cholesterol absorbing drug Zetia after some patients reported experiencing hypersensitivity reactions, including rashes and angio-oedema, a potentially life-threatening swelling of the face, neck, lips and throat...(more)
NHS negligence claims to be rationalised
A new national body to handle clinical negligence claims against the NHS has been proposed to speed up the process and limit unnecessary costs...(more)
NHS targets to flourish under 'arch moderniser
New Health Secretary Dr John Reid has committed the NHS to continued reform despite a growing chorus of disapproval over the central role of performance targets...(more)
Doctors shutting out sales reps
Doctors are making a conscious decision to give up less of their time to see sales reps, according to a new survey...(more)
US Senate backing for Canadian imports
The US Senate has backed a limited scheme to allow the parallel importation of drugs from Canada in order to save patients billions of dollars...(more)
|
|
|
|
|
|
|
|
|
|
|
